
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of marstacimab (Hympavzi) for treating bleeding episodes in people aged 12 years or older with severe hemophilia A and B.


coremsg

The drug will be available for patients aged 12 years and older and weighing at least 35 kg.

Hympavzi Recommended for Approval in Europe for Severe Hemophilia A, B

marstacimab-hympavzi-recommended-for-approval-in-europe-for-treating-severe-hemophilia-a-and-b


Marstacimab (Hympavzi) Recommended for Approval in Europe for Treating Severe Hemophilia A and B


title_rewrite


A new 21-valent pneumococcal conjugate vaccine, Capvaxive, has been approved by the FDA to protect adults against invasive pneumococcal disease and pneumococcal pneumonia.


The new vaccine covers eight serotypes not protected by other vaccines already on the market.

New Pneumococcal Vaccine Approved

new-21-valent-pneumococcal-vaccine-approved-for-adults-to-prevent-invasive-disease-and-pneumonia


New 21-Valent Pneumococcal Vaccine Approved for Adults to Prevent Invasive Disease and Pneumonia
